Stivarga
Payments companies reported to CMS as associated with Stivarga. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Stivarga, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Stivarga
These are the largest totals companies reported as associated with Stivarga. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Richard Kim | Tampa, FL | Hematology & Oncology | $15,229.78 |
| Jonathan Trent | Miami, FL | Medical Oncology | $15,146.27 |
| John Marshall | Washington, DC | Hematology & Oncology | $14,799.78 |
| Daniel Ahn | Scottsdale, AZ | Hematology & Oncology | $12,551.47 |
| Amit Singal | Dallas, TX | Hepatology | $12,484.74 |
| Afsaneh Barzi | Los Angeles, CA | Medical Oncology | $11,791.35 |
| Tanios Bekaii-Saab | Scottsdale, AZ | Hematology & Oncology | $11,247.85 |
| John Strickler | Durham, NC | Medical Oncology | $10,530.00 |
| Philip Philip | Detroit, MI | Medical Oncology | $6,390.00 |
| Marcus Noel | Rochester, NY | Medical Oncology | $5,047.00 |
Prescribed Stivarga?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.